Details of the Drug Combinations

General Information of This Drug (ID: DMVRLT7)

Drug Name
Fludarabine   DMVRLT7
Synonyms
FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Cutaneous melanoma 2C30 Approved [1]
Haematological malignancy 2B33.Y Approved [2]
Hematologic disease 3C0Z Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Immunodeficiency 4A00-4A85 Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lung cancer 2C25.0 Approved [1]
MALT lymphoma N.A. Approved [1]
Multiple sclerosis 8A40 Approved [1]
Myeloproliferative neoplasm 2A20 Approved [1]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Systemic lupus erythematosus 4A40.0 Approved [1]
Systemic sclerosis 4A42 Approved [1]
Testicular lymphoma N.A. Approved [1]
Classic Hodgkin lymphoma N.A. Investigative [1]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

283 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Fludarabine DCESWHV ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
ABIRATERONE + Fludarabine DCH0KFM ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [3]
ABIRATERONE + Fludarabine DCIKH3Q ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [3]
ABIRATERONE + Fludarabine DCY28A3 ABIRATERONE Amelanotic melanoma (Cell Line: M14) [4]
ABIRATERONE + Fludarabine DCT73GU ABIRATERONE Melanoma (Cell Line: MALME-3M) [4]
Amonafide + Fludarabine DC2B5S0 Amonafide Adenocarcinoma (Cell Line: DU-145) [3]
Amonafide + Fludarabine DCJ6I7B Amonafide Adenocarcinoma (Cell Line: NCIH23) [3]
Amonafide + Fludarabine DCICTR4 Amonafide Adenocarcinoma (Cell Line: HCT-15) [3]
Amonafide + Fludarabine DC67NDI Amonafide Adenocarcinoma (Cell Line: HCT116) [3]
Amonafide + Fludarabine DCQB2DD Amonafide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Amonafide + Fludarabine DCBW7AC Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Amonafide + Fludarabine DCXX0UV Amonafide Astrocytoma (Cell Line: U251) [3]
Amonafide + Fludarabine DCZQQQM Amonafide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Amonafide + Fludarabine DCTDNJI Amonafide Glioma (Cell Line: SF-268) [3]
Amonafide + Fludarabine DCOS106 Amonafide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Amonafide + Fludarabine DC08O4Q Amonafide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Amonafide + Fludarabine DCX2852 Amonafide Malignant melanoma (Cell Line: LOX IMVI) [3]
Amonafide + Fludarabine DCHEUC3 Amonafide Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Amonafide + Fludarabine DCXOK66 Amonafide Carcinoma (Cell Line: MCF7) [5]
Amonafide + Fludarabine DCAX3HC Amonafide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Amonafide + Fludarabine DCTVVZJ Amonafide Invasive ductal carcinoma (Cell Line: T-47D) [5]
Anastrozole + Fludarabine DC3PNQ6 Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Anastrozole + Fludarabine DCOX56R Anastrozole Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Anastrozole + Fludarabine DCDMWQX Anastrozole Chronic myelogenous leukemia (Cell Line: K-562) [3]
Anastrozole + Fludarabine DC1IQXN Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Anastrozole + Fludarabine DCIFRDC Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Anastrozole + Fludarabine DCJYH93 Anastrozole Melanoma (Cell Line: MALME-3M) [3]
Anastrozole + Fludarabine DCSU1GS Anastrozole Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Anastrozole + Fludarabine DCIUSUD Anastrozole Renal cell carcinoma (Cell Line: UO-31) [3]
Anastrozole + Fludarabine DC7E5SE Anastrozole Colon adenocarcinoma (Cell Line: COLO 205) [5]
Anastrozole + Fludarabine DCDGCSY Anastrozole Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Arfolitixorin + Fludarabine DCIJTTX Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Arfolitixorin + Fludarabine DC0OI8E Arfolitixorin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
BIO-300 + Fludarabine DC5O3FP BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
BIO-300 + Fludarabine DCK1DR3 BIO-300 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
BIO-300 + Fludarabine DCAGRIF BIO-300 Glioma (Cell Line: SF-539) [3]
BIO-300 + Fludarabine DC90M3E BIO-300 Glioma (Cell Line: SF-268) [3]
BIO-300 + Fludarabine DCFH5WA BIO-300 Invasive ductal carcinoma (Cell Line: T-47D) [5]
BIO-300 + Fludarabine DCZSWWZ BIO-300 Adenocarcinoma (Cell Line: DU-145) [4]
BIO-300 + Fludarabine DC4OXY5 BIO-300 Amelanotic melanoma (Cell Line: M14) [4]
BIO-300 + Fludarabine DCPPIGR BIO-300 Malignant melanoma (Cell Line: LOX IMVI) [4]
Bleomycin + Fludarabine DCM3L9G Bleomycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Bleomycin + Fludarabine DCQKGH3 Bleomycin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bleomycin + Fludarabine DCVDB6H Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bleomycin + Fludarabine DCD56WJ Bleomycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Bleomycin + Fludarabine DCWSY23 Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Cabazitaxel + Fludarabine DCXNZ0K Cabazitaxel Amelanotic melanoma (Cell Line: M14) [3]
Cabazitaxel + Fludarabine DCCT8L9 Cabazitaxel Astrocytoma (Cell Line: SNB-19) [3]
Cabazitaxel + Fludarabine DC2Z0RR Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Cabazitaxel + Fludarabine DC9EWEN Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [3]
Cabazitaxel + Fludarabine DC8KAGP Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Cabazitaxel + Fludarabine DCSXSIU Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Cabazitaxel + Fludarabine DC1ZIXJ Cabazitaxel Glioma (Cell Line: SF-295) [3]
Cabazitaxel + Fludarabine DCV8N02 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Cabazitaxel + Fludarabine DCHVUP1 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Cabazitaxel + Fludarabine DC0DAPH Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Crizotinib + Fludarabine DC86RAC Crizotinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Crizotinib + Fludarabine DCBA85U Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Crizotinib + Fludarabine DCUZQFH Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Crizotinib + Fludarabine DC7H8O2 Crizotinib Renal cell carcinoma (Cell Line: UO-31) [3]
Crizotinib + Fludarabine DCP7GDQ Crizotinib Renal cell carcinoma (Cell Line: SN12C) [3]
Crizotinib + Fludarabine DCTMN14 Crizotinib Colon carcinoma (Cell Line: KM12) [5]
Dacarbazine + Fludarabine DCZVHAE Dacarbazine Glioma (Cell Line: SF-268) [3]
Dacarbazine + Fludarabine DC8H3RO Dacarbazine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Dacarbazine + Fludarabine DCGD7TN Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Dactinomycin + Fludarabine DC1RM97 Dactinomycin Adenocarcinoma (Cell Line: DU-145) [4]
Dactinomycin + Fludarabine DC8APIG Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Dactinomycin + Fludarabine DCYJ8EF Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Dexrazoxane + Fludarabine DC7BZXV Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Dexrazoxane + Fludarabine DC2PDK2 Dexrazoxane Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Dexrazoxane + Fludarabine DC577E8 Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [4]
DFN-15 + Fludarabine DCYOM9Y DFN-15 Lung adenocarcinoma (Cell Line: EKVX) [4]
Fludarabine + Hepzato DC58D25 Hepzato Glioma (Cell Line: SF-295) [3]
Fludarabine + Dactinomycin DCPH26T Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Dactinomycin DCO2RZQ Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Dactinomycin DCDWE9H Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Fludarabine + PMID28460551-Compound-2 DCUNFMQ PMID28460551-Compound-2 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + PMID28460551-Compound-2 DCX18DD PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fludarabine + PMID28460551-Compound-2 DCPEFIF PMID28460551-Compound-2 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fludarabine + Isoniazid DC9CKMC Isoniazid Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + Arsenic trioxide DCNC862 Arsenic trioxide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + Arsenic trioxide DCE8WIZ Arsenic trioxide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fludarabine + Plicamycin DC2VCGH Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Plicamycin DC1O1RU Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Plicamycin DCYWEOE Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fludarabine + Nilotinib DCCNVS7 Nilotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Fludarabine + Nilotinib DCA31VU Nilotinib Glioma (Cell Line: SF-295) [3]
Fludarabine + 10-hydroxycamptothecin DCC314L 10-hydroxycamptothecin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Topetecan DCNVWCF Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Topetecan DCP6BSI Topetecan Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Pralatrexate DCD1WQU Pralatrexate Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + SCH 727965 DC1BWWZ SCH 727965 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fludarabine + Docetaxel DC7VCSX Docetaxel Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fludarabine + Raloxifene DCGICB4 Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Raloxifene DCKEU93 Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Sirolimus DCT0521 Sirolimus Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Mitomycin DCCLT26 Mitomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + Mitomycin DCMB52W Mitomycin Glioma (Cell Line: SF-539) [3]
Fludarabine + Bortezomib DC62M10 Bortezomib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Bortezomib DCB26FE Bortezomib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fludarabine + Valrubicin DC3RKU4 Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Fludarabine + Valrubicin DC7VBXK Valrubicin Glioblastoma (Cell Line: SNB-75) [3]
Fludarabine + Cisplatin DCBVJAC Cisplatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + Cisplatin DC9Y22H Cisplatin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Cisplatin DCK4VG6 Cisplatin Astrocytoma (Cell Line: U251) [3]
Fludarabine + Cisplatin DC8CDI3 Cisplatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Cisplatin DCOW8XH Cisplatin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fludarabine + Cisplatin DCE4J80 Cisplatin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fludarabine + Chlorambucil DCSYI0B Chlorambucil Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + Chlorambucil DCGL67U Chlorambucil Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + ER819762 DCYWB7Q ER819762 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Fludarabine + ER819762 DCMXSZH ER819762 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + ER819762 DC5WQ0W ER819762 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fludarabine + ER819762 DC44W46 ER819762 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fludarabine + ER819762 DCF8Z4P ER819762 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fludarabine + ER819762 DCUVI9V ER819762 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fludarabine + Romidepsin DCJLQ0B Romidepsin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Romidepsin DC96WF5 Romidepsin Glioma (Cell Line: SF-539) [3]
Fludarabine + Vinflunine DCHPRYJ Vinflunine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Fludarabine + Vinflunine DCCN7YT Vinflunine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Fludarabine + Mercaptopurine DCE0S9L Mercaptopurine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fludarabine + FORMESTANE DCARR3L FORMESTANE Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + FORMESTANE DCDXKV9 FORMESTANE Chronic myelogenous leukemia (Cell Line: K-562) [3]
Fludarabine + FORMESTANE DCDOCLJ FORMESTANE Glioma (Cell Line: SF-268) [3]
Fludarabine + Aminolevulinic Acid Hydrochloride DCCPZ9Y Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Aminolevulinic Acid Hydrochloride DC2IT87 Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Aminolevulinic Acid Hydrochloride DCGYNUP Aminolevulinic Acid Hydrochloride Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Aminolevulinic Acid Hydrochloride DCQE2B8 Aminolevulinic Acid Hydrochloride Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Fludarabine + Estramustine DCKMS3G Estramustine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Estramustine DCX694Y Estramustine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fludarabine + Digitoxin DCR46XO Digitoxin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Digitoxin DCK2NC0 Digitoxin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Busulfan DCZQXKC Busulfan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Busulfan DCB6X93 Busulfan Anaplastic large cell lymphoma (Cell Line: SR) [3]
Fludarabine + Dasatinib DCWCL5B Dasatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Fludarabine + Lapatinib DC5RZNI Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + PMID28460551-Compound-2 DCKK2LD PMID28460551-Compound-2 Carcinoma (Cell Line: RXF 393) [5]
Fludarabine + Arsenic trioxide DCRN2E2 Arsenic trioxide Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + Pralatrexate DCAST25 Pralatrexate Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + Terameprocol DCXJ4UB Terameprocol Carcinoma (Cell Line: MCF7) [5]
Fludarabine + Docetaxel DCUX23H Docetaxel Colon carcinoma (Cell Line: KM12) [5]
Fludarabine + Bendamustine hydrochloride DCFVSS8 Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: BT-549) [5]
Fludarabine + Vincristine DC25L5A Vincristine Colon carcinoma (Cell Line: KM12) [5]
Fludarabine + Bleomycin DCXJZAJ Bleomycin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + Chlorambucil DCK9U2O Chlorambucil Colon adenocarcinoma (Cell Line: COLO 205) [5]
Fludarabine + ER819762 DCOPDK0 ER819762 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Fludarabine + ER819762 DC2M7QB ER819762 Colon adenocarcinoma (Cell Line: COLO 205) [5]
Fludarabine + Romidepsin DCWI1D2 Romidepsin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Fludarabine + Azacitidine DCTLJ4B Azacitidine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Fludarabine + Pomalidomide DCB20LR Pomalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Fludarabine + Vinflunine DCCU0KV Vinflunine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + PMID28870136-Compound-43 DCQTW0E PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + Busulfan DCVM8AY Busulfan Carcinoma (Cell Line: MCF7) [5]
Fludarabine + Dasatinib DCEP3CN Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fludarabine + Pentostatin DCWLUK0 Pentostatin Adenocarcinoma (Cell Line: HCT-15) [4]
Fludarabine + Ruxolitinib DCUPM6R Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [4]
Fludarabine + Hepzato DCCHA7J Hepzato Adenocarcinoma (Cell Line: HT29) [4]
Fludarabine + Dactinomycin DCR1WPD Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
Fludarabine + Lapatinib DC44OE7 Lapatinib Adenocarcinoma (Cell Line: HCT-15) [4]
Fludarabine + PMID28460551-Compound-2 DCKIBCX PMID28460551-Compound-2 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Fludarabine + Cyclophosphamide DCM0FDQ Cyclophosphamide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Fludarabine + Isoniazid DCVZR52 Isoniazid Adenocarcinoma (Cell Line: A549) [4]
Fludarabine + Arsenic trioxide DCIESIP Arsenic trioxide Melanoma (Cell Line: MALME-3M) [4]
Fludarabine + Arsenic trioxide DCH60BS Arsenic trioxide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Fludarabine + Fomepizole DC7E6OW Fomepizole Hodgkin lymphoma (Cell Line: L-1236) [4]
Fludarabine + Plicamycin DCHHFMK Plicamycin Adenocarcinoma (Cell Line: NCIH23) [4]
Fludarabine + Nilotinib DCYS2FU Nilotinib Adenocarcinoma (Cell Line: DU-145) [4]
Fludarabine + Nilotinib DCNAN99 Nilotinib Adenocarcinoma (Cell Line: HT29) [4]
Fludarabine + Nilotinib DCJJWI5 Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Fludarabine + Nilotinib DC7LANY Nilotinib Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + Nilotinib DCLIBWN Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Fludarabine + Nilotinib DCHPC1D Nilotinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Fludarabine + Triapine DCROOSU Triapine Lung adenocarcinoma (Cell Line: EKVX) [4]
Fludarabine + Triapine DC46L54 Triapine Prostate carcinoma (Cell Line: PC-3) [4]
Fludarabine + 10-hydroxycamptothecin DCV55DR 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + 10-hydroxycamptothecin DCE13ZU 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Fludarabine + 10-hydroxycamptothecin DC095DA 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Fludarabine + Topetecan DCX3B3A Topetecan Adenocarcinoma (Cell Line: DU-145) [4]
Fludarabine + Topetecan DCL9PVC Topetecan Adenocarcinoma (Cell Line: HCT116) [4]
Fludarabine + Topetecan DCZJGBL Topetecan Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Fludarabine + Docetaxel DC8HM8U Docetaxel Adenocarcinoma (Cell Line: HT29) [4]
Fludarabine + Docetaxel DCP9JFU Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Fludarabine + Docetaxel DCR38QX Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Fludarabine + Docetaxel DCHE063 Docetaxel Melanoma (Cell Line: MALME-3M) [4]
Fludarabine + Raloxifene DCP3E8S Raloxifene Adenocarcinoma (Cell Line: OVCAR3) [4]
Fludarabine + Raloxifene DCVSUOD Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + Raloxifene DCCRD94 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Fludarabine + Raloxifene DCKZITN Raloxifene Malignant melanoma (Cell Line: UACC62) [4]
Fludarabine + Bendamustine hydrochloride DCLYNBA Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [4]
Fludarabine + Bendamustine hydrochloride DC1QTIZ Bendamustine hydrochloride Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Fludarabine + Sirolimus DCLEJ1S Sirolimus Adenocarcinoma (Cell Line: HCT116) [4]
Fludarabine + Sirolimus DCWSK7Z Sirolimus Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Fludarabine + Sirolimus DCVQ4H2 Sirolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Fludarabine + Mitomycin DCDCYZQ Mitomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Fludarabine + Vincristine DC1O002 Vincristine Lung adenocarcinoma (Cell Line: EKVX) [4]
Fludarabine + Bleomycin DCL11TU Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Fludarabine + Bortezomib DCLJ0FN Bortezomib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Fludarabine + Bortezomib DCGOFC6 Bortezomib Hodgkin lymphoma (Cell Line: L-1236) [4]
Fludarabine + Bortezomib DCYIUNH Bortezomib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Fludarabine + Valrubicin DCKFZK4 Valrubicin Adenocarcinoma (Cell Line: OVCAR3) [4]
Fludarabine + Valrubicin DCL0M5Q Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Fludarabine + Cisplatin DCO6N80 Cisplatin Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + Cisplatin DCWURV2 Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Fludarabine + Chlorambucil DCUDMTI Chlorambucil Adenocarcinoma (Cell Line: DU-145) [4]
Fludarabine + Chlorambucil DCZ9N5U Chlorambucil Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Fludarabine + ER819762 DCWRIAZ ER819762 Adenocarcinoma (Cell Line: A549) [4]
Fludarabine + ER819762 DC0PPYK ER819762 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Fludarabine + ER819762 DCLYCMS ER819762 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Fludarabine + ER819762 DC5P328 ER819762 Melanoma (Cell Line: MALME-3M) [4]
Fludarabine + ER819762 DC3C79X ER819762 Prostate carcinoma (Cell Line: PC-3) [4]
Fludarabine + Romidepsin DCP7E2H Romidepsin Adenocarcinoma (Cell Line: NCIH23) [4]
Fludarabine + Romidepsin DCQP24C Romidepsin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Fludarabine + Romidepsin DCSOU40 Romidepsin Melanoma (Cell Line: MALME-3M) [4]
Fludarabine + Azacitidine DCFK4BU Azacitidine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Fludarabine + Vinflunine DC44LEP Vinflunine Lung adenocarcinoma (Cell Line: EKVX) [4]
Fludarabine + Vinflunine DCW2QYL Vinflunine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Fludarabine + Taxol DCF0T6F Taxol Adenocarcinoma (Cell Line: HT29) [4]
Fludarabine + Aminolevulinic Acid Hydrochloride DCWB20R Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [4]
Fludarabine + Aminolevulinic Acid Hydrochloride DCV29SO Aminolevulinic Acid Hydrochloride Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + Aminolevulinic Acid Hydrochloride DCEP6DS Aminolevulinic Acid Hydrochloride Lung adenocarcinoma (Cell Line: HOP-62) [4]
Fludarabine + Digitoxin DC7OGH1 Digitoxin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Fludarabine + Digitoxin DCW6HZB Digitoxin Malignant melanoma (Cell Line: UACC62) [4]
Fludarabine + BGT226 DCD846Y BGT226 Hodgkin lymphoma (Cell Line: L-1236) [4]
Fludarabine + Oblimersen DCZVX50 Oblimersen Acute leukaemia (Cell Line: .) [6]
Gefitinib + Fludarabine DCBRZ6V Gefitinib Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Fludarabine DC2FLGY Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Fludarabine DC63JNR Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Fludarabine DC4YBGD Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Fludarabine DCSQZHO Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Fludarabine DCAWUIS Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Indazole derivative 5 + Fludarabine DCX82J0 Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Indazole derivative 5 + Fludarabine DC0BDS1 Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Indazole derivative 5 + Fludarabine DCHD6Q6 Indazole derivative 5 Astrocytoma (Cell Line: SNB-19) [3]
Indazole derivative 5 + Fludarabine DCGSC9Z Indazole derivative 5 Renal cell carcinoma (Cell Line: SN12C) [3]
JNK-IN-8 + Fludarabine DCKK6VM JNK-IN-8 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Letrozole + Fludarabine DC6FCWW Letrozole Adenocarcinoma (Cell Line: SW-620) [3]
Letrozole + Fludarabine DC3CBOU Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Letrozole + Fludarabine DCVR2UW Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
LIAROZOLE + Fludarabine DCGH005 LIAROZOLE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
LIAROZOLE + Fludarabine DC2BRCX LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
LIAROZOLE + Fludarabine DCKCXUL LIAROZOLE Astrocytoma (Cell Line: U251) [3]
LIAROZOLE + Fludarabine DCTHSYG LIAROZOLE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
LIAROZOLE + Fludarabine DC748U6 LIAROZOLE Chronic myelogenous leukemia (Cell Line: K-562) [3]
LIAROZOLE + Fludarabine DCKO4WZ LIAROZOLE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
LIAROZOLE + Fludarabine DC3VYTU LIAROZOLE Adenocarcinoma (Cell Line: OVCAR3) [4]
LIAROZOLE + Fludarabine DCKNZGE LIAROZOLE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Mechlorethamine + Fludarabine DC72ATW Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Methotrexate + Fludarabine DCAVF4P Methotrexate Lung adenocarcinoma (Cell Line: EKVX) [3]
PD-0325901 + Fludarabine DCMW9C0 PD-0325901 Ewing sarcoma (Cell Line: TC-71) [3]
Raloxifene + Fludarabine DCJR79O Raloxifene Anaplastic large cell lymphoma (Cell Line: SR) [3]
Raloxifene + Fludarabine DC7QBKM Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Ruxolitinib + Fludarabine DCJG2ET Ruxolitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Ruxolitinib + Fludarabine DCFT49J Ruxolitinib Colon carcinoma (Cell Line: KM12) [5]
Ruxolitinib + Fludarabine DCJ554J Ruxolitinib Adenocarcinoma (Cell Line: DU-145) [4]
Thioguanine + Fludarabine DCYQZQG Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Topotecan + Fludarabine DCRXOFP Topotecan Carcinoma (Cell Line: MCF7) [5]
Topotecan + Fludarabine DCY11HO Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Topotecan + Fludarabine DCP1CR7 Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Topotecan + Fludarabine DC6SPDM Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Topotecan + Fludarabine DCHMH3D Topotecan Glioblastoma (Cell Line: SNB-75) [4]
Topotecan + Fludarabine DCI6LN4 Topotecan Glioma (Cell Line: SF-268) [4]
Topotecan + Fludarabine DCQBQOA Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + Fludarabine DC8154U Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Topotecan + Fludarabine DC0C227 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Topotecan + Fludarabine DCMO7YH Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Trifluridine + Fludarabine DCHME68 Trifluridine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Uracil mustard + Fludarabine DC893PP Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Uracil mustard + Fludarabine DC7WPAR Uracil mustard Glioma (Cell Line: SF-295) [3]
Uracil mustard + Fludarabine DCA6BXQ Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Uracil mustard + Fludarabine DCDRTJ3 Uracil mustard Adenocarcinoma (Cell Line: DU-145) [4]
Uracil mustard + Fludarabine DCD1JEF Uracil mustard Adenocarcinoma (Cell Line: HT29) [4]
Uracil mustard + Fludarabine DCHDG9Q Uracil mustard Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Uracil mustard + Fludarabine DCEOXYO Uracil mustard Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Fludarabine DCAN2EL Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Fludarabine DCXDOKR Vandetanib Malignant melanoma (Cell Line: UACC62) [4]
Vandetanib + Fludarabine DCEVXPF Vandetanib Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Fludarabine DCOC9SG Vandetanib Renal cell carcinoma (Cell Line: SN12C) [4]
Vemurafenib + Fludarabine DCDD3N5 Vemurafenib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Vemurafenib + Fludarabine DC53FMX Vemurafenib Malignant melanoma (Cell Line: UACC62) [4]
Vemurafenib + Fludarabine DCCD25Z Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [4]
Vismodegib + Fludarabine DCRE8GI Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vismodegib + Fludarabine DCGHRL4 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vismodegib + Fludarabine DC3W3U3 Vismodegib Renal cell carcinoma (Cell Line: SN12C) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 283 DrugCom(s)
25 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Aminooxyacetic acid + Fludarabine DCD74NV Aminooxyacetic acid Adult Nasal Type Extranodal NK/T-cell Lymphoma [7]
Bortezomib + Fludarabine DCSEHGD Bortezomib Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue [8]
Cyclophosphamide + Fludarabine DCYPH5P Cyclophosphamide Epidermolysis Bullosa [9]
Cyclophosphamide + Fludarabine DC1WBPB Cyclophosphamide Melanoma [10]
Cyclophosphamide + Fludarabine DCQFTOE Cyclophosphamide Follicular Lymphoma [11]
Cyclophosphamide + Fludarabine DCLZQC3 Cyclophosphamide Acute Lymphoblastic Leukemia, in Relapse [12]
Flavopiridol + Fludarabine DCPJKXG Flavopiridol B-cell Chronic Lymphocytic Leukemia [13]
Fludarabine + Busulfan DCMXG0T Busulfan Diamond-Blackfan Anemia [14]
Fludarabine + CATECHIN DCKC5EJ CATECHIN Hematological Malignancies [15]
Idelalisib + Fludarabine DCFC49D Idelalisib Indolent Non-Hodgkin's Lymphoma [16]
Ifosfamide + Fludarabine DCBQ36A Ifosfamide Acute Myeloid Leukemia [17]
Lenalidomide + Fludarabine DCE8HNC Lenalidomide Leukemia, Lymphocytic, Chronic, B-Cell [18]
Levetiracetam + Fludarabine DCASDHE Levetiracetam Hematologic Disorders [19]
Melphalan + Fludarabine DCOSRRA Melphalan Accelerated Phase Chronic Myelogenous Leukemia [20]
Methotrexate + Fludarabine DCSJX87 Methotrexate Acute Myeloid Leukemia [21]
Mycophenolate mofetil + Fludarabine DCS54G5 Mycophenolate mofetil Systemic Scleroderma [22]
Mycophenolic acid + Fludarabine DC5CVAU Mycophenolic acid Systemic Scleroderma [23]
Romidepsin + Fludarabine DC2WH9H Romidepsin Recurrent Grade 1 Follicular Lymphoma [24]
Thiotepa + Fludarabine DCFXMSL Thiotepa Leukemia [25]
Clofarabine + Fludarabine DC2J2YF Clofarabine Myeloid Malignancy [26]
Fludarabine + Ibrutinib DCHNM7Y Ibrutinib Chronic Lymphocytic Leukemia [27]
Methotrexate + Fludarabine DCPTTD8 Methotrexate Accelerated Phase Chronic Myelogenous Leukemia [28]
Pacritinib + Fludarabine DCCBV19 Pacritinib Myeloproliferative Diseases [29]
Thiotepa + Fludarabine DCEDCHE Thiotepa Acute Myeloid Leukaemia [30]
Fludarabine + Cytarabine DCG7WXH Cytarabine Acute Myeloid Leukemia [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 DrugCom(s)

References

1 Fludarabine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4802).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
7 ClinicalTrials.gov (NCT01658319) Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
8 ClinicalTrials.gov (NCT00068315) Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
9 ClinicalTrials.gov (NCT00478244) Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
10 ClinicalTrials.gov (NCT00001832) Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
11 ClinicalTrials.gov (NCT01303887) A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
12 ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
13 ClinicalTrials.gov (NCT00058227) Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
14 ClinicalTrials.gov (NCT00176878) Stem Cell Transplant for Bone Marrow Failure Syndromes
15 ClinicalTrials.gov (NCT03344705) Safety and Efficacy Evaluation of IM19 Cells
16 ClinicalTrials.gov (NCT01088048) Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
17 ClinicalTrials.gov (NCT04167696) Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1). U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT00738829) Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
19 ClinicalTrials.gov (NCT01666080) Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
20 ClinicalTrials.gov (NCT00856388) Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
21 ClinicalTrials.gov (NCT02129582) Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
22 ClinicalTrials.gov (NCT01047072) Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
23 ClinicalTrials.gov (NCT00622895) Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
24 ClinicalTrials.gov (NCT00079443) FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
25 ClinicalTrials.gov (NCT00392782) Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
26 ClinicalTrials.gov (NCT01596699) Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
27 ClinicalTrials.gov (NCT02514083) A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
28 ClinicalTrials.gov (NCT01056614) Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
29 ClinicalTrials.gov (NCT02410551) Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
30 ClinicalTrials.gov (NCT04217278) A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
31 ClinicalTrials.gov (NCT02024308) AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy